The latest price target for Fresenius Medical Care (NYSE:FMS) was reported by Truist Securities on July 31, 2024. The analyst firm set a price target for $22.00 expecting FMS to rise to within 12 months (a possible 8.37% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Fresenius Medical Care (NYSE:FMS) was provided by Truist Securities, and Fresenius Medical Care maintained their hold rating.

The last upgrade for Fresenius Medical Care AG happened on November 24, 2023 when HSBC raised their price target to N/A. HSBC previously had a reduce for Fresenius Medical Care AG.

There is no last downgrade for Fresenius Medical Care.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fresenius Medical Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fresenius Medical Care was filed on July 31, 2024 so you should expect the next rating to be made available sometime around July 31, 2025.

While ratings are subjective and will change, the latest Fresenius Medical Care (FMS) rating was a maintained with a price target of $24.00 to $22.00. The current price Fresenius Medical Care (FMS) is trading at is $20.30, which is out of the analyst’s predicted range.